REZOLV3R | ACTRN12624000288527
The REZOLV3R trial compares post treatment paracentesis free survival time between each treatment group (bevacizumab or control). The aim is to improve quality of life and optimise management of patients with advanced cancers with recurrent malignant ascites in the [...]





